论文信息 - Impact of guselkumab on three cases of SSc accompanying psoriasis. - 字舞流文

Impact of guselkumab on three cases of SSc accompanying psoriasis.

A. Yoshizaki | T. Fukasawa | Shinichi Sato | A. Yoshizaki-Ogawa

[1] H. Sumida,et al. Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial. , 2023, Journal of the American Academy of Dermatology.

[2] K. Miyagawa,et al. Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study. , 2022, Rheumatology.

[3] A. Enomoto,et al. Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model , 2021, eLife.

[4] M. Mayes,et al. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis , 2016, Arthritis & rheumatology.

[5] M. Mayes,et al. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[6] R. D. Hatton,et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[7] R. Langley,et al. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. , 2004, Journal of the American Academy of Dermatology.

[8] O. Kawamura,et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD , 2004, Journal of Gastroenterology.